{
    "organizations": [],
    "uuid": "8624726d13ec05bbb8870177d583ab6ccfc0fde4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adamas-announces-us-commercial-lau/brief-adamas-announces-u-s-commercial-launch-of-gocovri-the-first-fda-approved-medication-for-treatment-of-dyskinesiain-parkinsons-disease-patients-idUSFWN1P30WR",
    "ord_in_thread": 0,
    "title": "BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Adamas Pharmaceuticals Inc:\n* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T23:44:00.000+02:00",
    "crawled": "2018-01-09T10:07:32.779+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "adamas",
        "pharmaceutical",
        "inc",
        "adamas",
        "announces",
        "commercial",
        "launch",
        "first",
        "medication",
        "treatment",
        "dyskinesia",
        "parkinson",
        "disease",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}